Aurobindo Pharma is currently trading at Rs. 1165.00, up by 41.85 points or 3.73% from its previous closing of Rs. 1123.15 on the BSE.
The scrip opened at Rs. 1128.00 and has touched a high and low of Rs. 1166.00 and Rs. 1128.00 respectively. So far 53,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1171.20 on 09-Dec-2014 and a 52 week low of Rs. 295.50 on 13-Dec-2013.
Last one week high and low of the scrip stood at Rs. 1171.20 and Rs. 1108.00 respectively. The current market cap of the company is Rs. 33,973.00 crore.
The promoters holding in the company stood at 54.10%, while Institutions and Non-Institutions held 35.67% and 10.22% respectively.
Aurobindo Pharma has received approval for the issue of equity shares through qualified institutions placement up to $350 million. The board at its meeting held on December 10, 2014 has approved for the same. At the aforesaid meeting, it has also been decided to hold a general meeting of the members of the Company for the above purpose on January 21, 2015.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1676.80 |
| Dr. Reddys Lab | 1236.95 |
| Cipla | 1237.00 |
| Zydus Lifesciences | 940.75 |
| Lupin | 2338.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: